Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 4/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | SLC16A3 | O15427 | 2/20 | 0.46 |
| ▸ | SLC16A1 | P53985 | 2/20 | 0.46 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1793712 | 1.00 | EGFR (0.53) | EGFRKDM4ELMNAPKMKMT2A | |
| SCHEMBL30980828 | 1.00 | EGFR (0.53) | EGFRKDM4ELMNAPKMKMT2A | |
| SCHEMBL2461183 | 0.83 | EGFR (0.54) | EGFRKDM4ELMNAPKMKMT2A | |
| SCHEMBL14689741 | 0.83 | EGFR (0.54) | EGFRKDM4ELMNAPKMKMT2A | |
| SCHEMBL14689784 | 0.82 | EGFR (0.50) | EGFRKDM4ELMNAPKMKMT2A | |
| SCHEMBL2461928 | 0.82 | EGFR (0.50) | EGFRKDM4ELMNAPKMKMT2A | |
| SCHEMBL2462518 | 0.81 | EGFR (0.46) | EGFRKDM4ESLC16A3SLC16A1CISD1 | |
| SCHEMBL14689882 | 0.81 | EGFR (0.46) | EGFRKDM4ESLC16A3SLC16A1CISD1 | |
| SCHEMBL2029718 | 0.80 | KDM4E (0.60) | EGFRKDM4ELMNAPKMKMT2A | |
| SCHEMBL1711226 | 0.80 | KDM4E (0.60) | EGFRKDM4ELMNAPKMKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2542897-B1 | Use of halogenated cyanocinnamic acid derivatives as matrices in MALDI mass spectrometry | SIGMA ALDRICH INTERNAT GMBH (CH) | 2015-06-17 | — | — | EP | claimed |
| US-8980642-B2 | Use of cyanocinnamic acid derivatives as matrics in MALDI mass spectrometry | SIGMA-ALDRICH INTERNATIONAL GMBH (CH) | 2015-03-17 | — | — | US | claimed |
| EP-2183600-B1 | USE OF CYANOCINNAMIC ACID DERIVATIVES AS MATRICES IN MALDI MASS SPECTROMETRY | SIGMA ALDRICH INTERNAT GMBH (CH) | 2014-09-03 | — | — | EP | claimed |
| US-20130040395-A1 | USE OF HALOGENATED DERIVATIVES OF THE CYANOCINNAMIC ACID AS MATRICES IN MALDI MASS SPECTROMETRY | Johann Wolfgang Goethe-Universität (DE) | 2013-02-14 | — | — | US | claimed |
| US-20110121166-A1 | USE OF CYANOCINNAMIC ACID DERIVATIVES AS MATRICS IN MALDI MASS SPECTROMETRY | JOHANN WOLFGANG GOETHE-UNIVERSITAT | 2011-05-26 | — | — | US | claimed |
| US-20250102517-A1 | ARTICLES AND METHODS INVOLVING DETECTION OF BINDING | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (US) | 2025-03-27 | — | — | US | disclosed |
| US-12135330-B2 | Articles and methods involving detection of binding | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (US) | 2024-11-05 | — | — | US | disclosed |
| EP-4407317-A2 | ARTICLES AND METHODS INVOLVING DETECTION OF BINDING | Charles River Laboratories, Inc. (US) | 2024-07-31 | — | — | EP | disclosed |
| EP-3601609-B1 | ARTICLES AND METHODS INVOLVING DETECTION OF BINDING | CHARLES RIVER LABORATORIES INC (US) | 2024-07-03 | — | — | EP | disclosed |
| EP-3601609-A1 | ARTICLES AND METHODS INVOLVING DETECTION OF BINDING | Samdi Tech, Inc. (US) | 2020-02-05 | — | — | EP | disclosed |
| WO-2018183482-A1 | ARTICLES AND METHODS INVOLVING DETECTION OF BINDING | SAMDI TECH, INC. (US) | 2018-10-04 | — | — | WO | disclosed |
| US-8980642-B2 | Use of cyanocinnamic acid derivatives as matrics in MALDI mass spectrometry | SIGMA-ALDRICH INTERNATIONAL GMBH (CH) | 2015-03-17 | — | — | US | disclosed |
| US-20130040395-A1 | USE OF HALOGENATED DERIVATIVES OF THE CYANOCINNAMIC ACID AS MATRICES IN MALDI MASS SPECTROMETRY | Johann Wolfgang Goethe-Universität (DE) | 2013-02-14 | — | — | US | disclosed |
| US-20110121166-A1 | USE OF CYANOCINNAMIC ACID DERIVATIVES AS MATRICS IN MALDI MASS SPECTROMETRY | JOHANN WOLFGANG GOETHE-UNIVERSITAT | 2011-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130040395-A1 | USE OF HALOGENATED DERIVATIVES OF THE CYANOCINNAMIC ACID AS MATRICES IN MALDI MASS SPECTROMETRY | DOHH, DBH, CBR3 | EGFR 1800/4885KDM4E 3943/4885LMNA 924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.